Literature DB >> 32650109

The COVID-19 pandemic and the true incidence of Tuberculosis in Japan.

Kosaku Komiya1, Mari Yamasue2, Osamu Takahashi3, Kazufumi Hiramatsu2, Jun-Ichi Kadota2, Seiya Kato4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32650109      PMCID: PMC7338857          DOI: 10.1016/j.jinf.2020.07.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear editor, A recent report in the present journal focused on the decreased incidence of tuberculosis during the COVID-19 pandemic in Taiwan. A declining trend in influenza following the COVID-19 outbreak has already been indicated in Brazil, Singapore and Japan.2, 3, 4 According to the Infectious Diseases Weekly Report Japan, besides influenza, the incidences of Mycoplasma pneumoniae pneumonia, respiratory syncytial virus infection, infectious gastroenteritis, epidemic keratoconjunctivitis and other droplet or contact transmission diseases are also markedly lower than those in the same periods in previous years. The COVID-19 pandemic has brought about lifestyle changes, including the encouragement of wearing masks, handwashing, maintaining social distance and suspension of mass gatherings. These prevention measures for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission may have contributed to a decline in many types of infectious diseases. Lai et al. suggested that these interventions for infection control may also positively influence pulmonary tuberculosis. However, whether or not the decline in tuberculosis incidence is actually due to these prevention measures, as with other respiratory infectious diseases, is unclear. Tuberculosis can be pathologically divided into primary and secondary (reactivation) tuberculosis. An increase in the numbers of elderly patients with newly diagnosed tuberculosis has been observed worldwide, and this disease typically develops as a result of reactivation of a latent tuberculosis infection a long time, usually several dozen years, after the initial tuberculosis infection. As such, the infection control measures enacted to prevent SARS-CoV-2 transmission a short time after the COVID-19 outbreak are not expected to influence the trend in tuberculosis incidence. In Japan, as seen in Taiwan, the number of patients newly diagnosed with tuberculosis has significantly decreased since the COVID-19 outbreak, especially in March 2020 (Fig. 1 ). As Lai et al. mentioned, the number of tests for Mycobacterium tuberculosis detection may be confounded with whether or not the COVID-19 outbreak reduced the rate of tuberculosis identification through alternations in the behavior of symptomatic individuals seeking medical attention or in physicians’ inclination to test for M. tuberculosis. Indeed, the COVID-19 pandemic required lockdowns in many areas and restricted access to hospitals, especially for people with non-emergent symptoms. Medical checkups have also been canceled or delayed. Such a situation can deprive physicians of opportunities to suspect tuberculosis infection and test for M. tuberculosis.
Fig. 1

Number of patients newly diagnosed with tuberculosis in Japan. The incidence in each month differed significantly among 2017, 2018, 2019, and 2020 (p < 0.01 for each by chi-square test), and the incidence in 2020 was significantly lower than that in 2017, 2018, or 2019 from February to April (p < 0.002 for each by Ryan's multiple comparison test). In April, no significant difference was noted in the incidence among 2017, 2018, and 2019, but the incidence in April 2020 was significantly lower than that in 2017, 2018, or 2019. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Number of patients newly diagnosed with tuberculosis in Japan. The incidence in each month differed significantly among 2017, 2018, 2019, and 2020 (p < 0.01 for each by chi-square test), and the incidence in 2020 was significantly lower than that in 2017, 2018, or 2019 from February to April (p < 0.002 for each by Ryan's multiple comparison test). In April, no significant difference was noted in the incidence among 2017, 2018, and 2019, but the incidence in April 2020 was significantly lower than that in 2017, 2018, or 2019. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) We therefore examined data regarding the number of acid-fast bacteria cultures submitted to the SRL, the largest commercial laboratory in Japan, and compared changes from January to May in 2020 with the same period in 2017, 2018, and 2019. The data were kindly provided by SRL. Our results showed that the number of tests decreased starting in April in 2020, and the numbers of tests in April and May 2020 were significantly lower than those in the same period of 2017–2019, as shown in Fig. 2 .
Fig. 2

Number of acid-fast bacteria cultures reviewed at the largest commercial laboratory in Japan. The number of tests per month differed significantly among 2017, 2018, 2019, and 2020 (p < 0.01 for each by chi-square test), and the number in 2020 was significantly lower than that in 2017, 2018, or 2019 in April and May (p < 0.002 for each by Ryan's multiple comparison test). In April, no significant difference was noted in the number between 2018 and 2019, but the number in April 2020 was significantly lower than that in 2017, 2018, or 2019. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Number of acid-fast bacteria cultures reviewed at the largest commercial laboratory in Japan. The number of tests per month differed significantly among 2017, 2018, 2019, and 2020 (p < 0.01 for each by chi-square test), and the number in 2020 was significantly lower than that in 2017, 2018, or 2019 in April and May (p < 0.002 for each by Ryan's multiple comparison test). In April, no significant difference was noted in the number between 2018 and 2019, but the number in April 2020 was significantly lower than that in 2017, 2018, or 2019. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Consequently, the statistical decline in tuberculosis incidence following the COVID-19 outbreak is likely to have been influenced by the decreased number of tests for M. tuberculosis and may not reflect the true incidence of tuberculosis in Japan. Because the reactivation of tuberculosis among the elderly cannot be controlled by short term measures for preventing SARS-CoV-2 transmission, physicians need to be aware of the possibility of underestimated tuberculosis infection and carefully examine elderly patients considering the likelihood of tuberculosis infection.

Declaration of Competing Interest

None.
  9 in total

1.  Incidence of common infectious diseases in Japan during the COVID-19 pandemic.

Authors:  Kenji Hibiya; Hiroyoshi Iwata; Takeshi Kinjo; Akira Shinzato; Masao Tateyama; Shinichiro Ueda; Jiro Fujita
Journal:  PLoS One       Date:  2022-01-12       Impact factor: 3.240

2.  Changes in Temporal Properties of Notifiable Infectious Disease Epidemics in China During the COVID-19 Pandemic: Population-Based Surveillance Study.

Authors:  Xixi Zhao; Meijia Li; Naem Haihambo; Jianhua Jin; Yimeng Zeng; Jinyi Qiu; Mingrou Guo; Yuyao Zhu; Zhirui Li; Jiaxin Liu; Jiayi Teng; Sixiao Li; Ya-Nan Zhao; Yanxiang Cao; Xuemei Wang; Yaqiong Li; Michel Gao; Xiaoyang Feng; Chuanliang Han
Journal:  JMIR Public Health Surveill       Date:  2022-06-23

3.  Lymphocyte Non-Specific Function Detection Facilitating the Stratification of Mycobacterium tuberculosis Infection.

Authors:  Ying Luo; Ying Xue; Yimin Cai; Qun Lin; Guoxing Tang; Huijuan Song; Wei Liu; Liyan Mao; Xu Yuan; Yu Zhou; Weiyong Liu; Shiji Wu; Ziyong Sun; Feng Wang
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

4.  The impact of the COVID-19 pandemic and associated suppression measures on the burden of tuberculosis in India.

Authors:  Matthew Arentz; Jianing Ma; Peng Zheng; Theo Vos; Christopher J L Murray; Hmwe H Kyu
Journal:  BMC Infect Dis       Date:  2022-01-27       Impact factor: 3.090

5.  Retrospective Cohort Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020.

Authors:  Tasnim Hasan; Viet Nhung Nguyen; Hoa Binh Nguyen; Thu Anh Nguyen; Hien T T Le; Cuong D Pham; Nam Hoang; Phuong T M Nguyen; Justin Beardsley; Guy B Marks; Greg J Fox
Journal:  Emerg Infect Dis       Date:  2022-03       Impact factor: 6.883

Review 6.  Competing health risks associated with the COVID-19 pandemic and early response: A scoping review.

Authors:  Stefan Baral; Amrita Rao; Jean Olivier Twahirwa Rwema; Carrie Lyons; Muge Cevik; Anna E Kågesten; Daouda Diouf; Annette H Sohn; Refilwe Nancy Phaswana-Mafuya; Adeeba Kamarulzaman; Gregorio Millett; Julia L Marcus; Sharmistha Mishra
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

7.  Impact of COVID-19 Pandemic on Pre-Treatment Delays, Detection, and Clinical Characteristics of Tuberculosis Patients in Ningxia Hui Autonomous Region, China.

Authors:  Xiaolin Wang; Wencong He; Juan Lei; Guangtian Liu; Fei Huang; Yanlin Zhao
Journal:  Front Public Health       Date:  2021-05-21

Review 8.  Effects of COVID-19 prevention procedures on other common infections: a systematic review.

Authors:  Omid Dadras; Seyed Ahmad Seyed Alinaghi; Amirali Karimi; Mehrzad MohsseniPour; Alireza Barzegary; Farzin Vahedi; Zahra Pashaei; Pegah Mirzapour; Amirata Fakhfouri; Ghazal Zargari; Solmaz Saeidi; Hengameh Mojdeganlou; Hajar Badri; Kowsar Qaderi; Farzane Behnezhad; Esmaeil Mehraeen
Journal:  Eur J Med Res       Date:  2021-07-03       Impact factor: 2.175

9.  Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection.

Authors:  Ying Luo; Ying Xue; Guoxing Tang; Yimin Cai; Xu Yuan; Qun Lin; Huijuan Song; Wei Liu; Liyan Mao; Yu Zhou; Zhongju Chen; Yaowu Zhu; Weiyong Liu; Shiji Wu; Feng Wang; Ziyong Sun
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.